Phase Ib trial of the PI3K/mTOR inhibitor voxtalisib (SAR245409) in combination with chemoimmunotherapy in patients with relapsed or refractory B‐cell malignancies

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2141|175|1|55-65

ISSN： 0007-1048

Source： BRITISH JOURNAL OF HAEMATOLOGY, Vol.175, Iss.1, 2016-10, pp. : 55-65

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Phase 1/1B trial of the heat shock protein 90 inhibitor NVP‐AUY922 as monotherapy or in combination with bortezomib in patients with relapsed or refractory multiple myeloma

By  

CANCER, Vol. 121, Iss. 13, 2015-07 ,pp. : 2185-2192

John Wiley & Sons Inc

Access to resources Recommend Favorite

Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20+ lymphoid malignancies

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 170, Iss. 5, 2015-09 ,pp. : 669-678

John Wiley & Sons Inc

Access to resources Recommend Favorite

A phase II trial of AZD1152 in relapsed/refractory diffuse large B‐cell lymphoma

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 170, Iss. 6, 2015-09 ,pp. : 886-890

John Wiley & Sons Inc

Access to resources Recommend Favorite

Rhinitis in Patients Treated with a Combination of an mTOR Inhibitor and an EGFR Inhibitor

By  

Oncology Research and Treatment, Vol. 33, Iss. 7, 2010-06 ,pp. : 401-402

Karger

Access to resources Recommend Favorite

Phase I/II trial of vorinostat with rituximab, cyclophosphamide, etoposide and prednisone as palliative treatment for elderly patients with relapsed or refractory diffuse large B‐cell lymphoma not eligible for autologous stem cell transplantation

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 168, Iss. 5, 2015-03 ,pp. : 663-670

John Wiley & Sons Inc

Access to resources Recommend Favorite